AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02603120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABC/DTG/3TC
Description: 600/50/300 mg FDC tablets administered orally once daily without regard to food
Study NCT02603120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg FDC tablets administered orally once daily without regard to food
Study NCT02603120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC/DTG/3TC Placebo
Description: Tablets administered orally once daily without regard to food
Study NCT02603120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B/F/TAF Placebo
Description: Tablets administered orally once daily without regard to food
Study NCT03094234 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 8mm-TIPS
Description: Patients in this group would underwent TIPS placement with 8mm-diameter ePTFE-covered stents.
Study NCT03094234 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic variceal ligation (EVL)
Description: Patients in this group would underwent sequential endoscopic variceal ligation and propranolol treatment.
Study NCT03094234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Appropriate dose of propranolol was administered to the patients.
Study NCT04216277 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Procalcitonin
Description: In addition to usual care diagnostic and handling of acute respiratory tract infections in general practice to attending physician in the intervention arm has access to antibiotic stewardship by a procalcitonin point-of-care test. The following criteria for initiating og withholding antibiotics will be used.~* Antibiotics treatment is recommended with Procalcitonin levels above 0.25 ng/ml~* Antibiotic treatment is discouraged if Procalcitonin levels are below 0.25 ng/ml
Study NCT02218281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: C2Q-Teen app
Description: Commit to Quit (C2Q)-Teen app provides smoking cessation assistance incorporating mindfulness training.
Study NCT02218281 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NCI's QuitSTART app
Description: NCI's smoking cessation app
Study NCT02218281 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written smoking cessation materials only
Description: Receipt of written smoking cessation materials
Study NCT00529997 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stabilimax NZ® Dynamic Spine Stabilization System
Description: Surgical Implantation
Study NCT00529997 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stabilimax NZ® Dynamic Spine Stabilization System
Description: Surgical Implantation
Study NCT03186677 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg
Description: ISU304/CB2679d/Dalcinonacog alfa 75\~150 IU/kg by intravenous or subcutaneous
Study NCT03186677 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BeneFIX
Description: BeneFIX 75 IU/kg, intravenous administration
Study NCT04135430 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: practice of an updated questionnaire at D0, D2 and D7
Study NCT01916837 — intervention group
Intervention type: OTHER
Intervention: Sampling of tumor tissue
Description: Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery
Study NCT01916837 — intervention group
Intervention type: OTHER
Intervention: Sampling of tumor tissue after breast cancer surgery
Description: Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery
Study NCT01916837 — intervention group
Intervention type: PROCEDURE
Intervention: Sampling of tumor tissue after breast cancer surgery
Description: Fresh tumor specimens were sampled prior to adding any fixative and within one hour of surgery
Study NCT04077307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Karonudib
Description: First part of the study - four different dose cohorts Extension part of the study - karonudib BID (twice a week) and Idarubicin days 1-3.
Study NCT01750385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: no antibiotic prophylaxis
Description: These patients are in no antibiotic prophylaxis group will not be administered antibiotic prophylactically.
Study NCT01750385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: second-generation cephalosporin
Description: These patients are in antibiotic prophylaxis group will be administered second-generation cephalosporin prophylactically.
Study NCT01351935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVL-292
Description: 125 mg to 625 mg orally, once a day, for 28 days (28 days equals 1 cycle). Number of cycles: until progression or unacceptable toxicity develops
Study NCT01408992 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Audiometry
Description: Standard hearing test performed by audiologists
Study NCT01408992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thai-Five Minute Hearing Test
Description: All subjects will be interviewed with Thai-Five Minute Hearing Test
Study NCT04064502 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CHRONIC ANKLE INSTABILITY AND ASSOCIATED FACTORS:
Description: Questionnaire including sociodemographic information, general medical condition, history of orthopedic surgery, pain intensity, and the number of painful areas of the foot.
Study NCT04082871 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication management review
Description: The researcher screened each completed an MMR template and verified that all information in each patient template was complete. A classification system was then used to identify the TRPs which either actually or potentially interfered with the clinical outcomes for each patient.\[19\] This system was explained in detail and applied successfully in many previous studies.\[10, 14, 20\] The researcher then identified TRPs for each patient in both groups using evidence-based medicine. The TRPs including unneeded drug treatment, untreated condition/s, efficacy/effectiveness issues, safety issues, inadequate knowledge, inappropriate adherence to pharmacological therapy, inappropriate adherence to self-care activities and miscellaneous problems.
Study NCT01206062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive control of SBP
Description: Participants in the Intensive arm have a goal of SBP \<120 mm Hg. Use of once-daily antihypertensive agents will be encouraged unless alternative frequency is indicated/necessary. One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals:~Angiotension converting enzyme (ACE)-inhibitors Angiotension receptor blockers (ARBs) Direct vasodilators Thiazide-type diuretics Loop diuretics Potassium-sparing diuretics Beta-blockers Sustained-release calcium channel blockers (CCBs) Alpha1-receptor blockers Sympatholytics~Combination products will be available, depending on cost, utility, or donations from pharmaceutical companies.
Study NCT01206062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard control of SBP
Description: Participants in the Standard BP arm have a goal of SBP \<140 mm Hg. The same medications used in the Intensive BP arm will be used for the Standard BP arm.
Study NCT02500680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MER4101
Study NCT02500680 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Influenza Vaccine
Description: Fluzone quadrivalent Influenza Vaccine
Study NCT02318862 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of Care esophagogastroduodenoscopy (EGD) with mucosal impedance testing
Study NCT01819051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOE Antimicrobial Plasma Treatment System
Description: Plasma applied to great toenail 1X/week for three weeks
Study NCT00670319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene HCL
Description: Raloxifene HCL 60 mg orally once daily
Study NCT00670319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene HCL
Description: Raloxifene HCL 120 mg orally once daily
Study NCT00670319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo one tab orally per day
Study NCT03114176 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: Diet consisted of a very low carbohydrate ketogenic diet (for 7 days) with the use of some phytoextracts as previously described. The consumed diet was primarily made of beef and veal, poultry, fish, raw and cooked green vegetables without restrictions, cold cuts (dried beef, carpaccio and cured ham), eggs and seasoned cheese (e.g., parmesan). The allowed drinks were infused tea, moka coffee and herbal extracts. The foods and drinks that subjects had to avoid included alcohol, bread, pasta, rice, milk, yogurt, soluble tea, and barley coffee. To facilitate adherence to the nutritional regime, a variety of special meals based on protein and fibers were given to each subject. KD characteristics are protein intake 1.3g/kg/day, to maintain skeletal muscle mass; carbohydrates intake less than 40 g/day and 50-60% of total kcal to induce ketosis. In accordance with a hypocaloric profile, total energy intake was calculated with 200 kcal more than basal metabolic rate.
Study NCT01308008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home exercise/physical activity (PA) enhancement program with behavioral support
Description: Initial on-site personal trainer-based functional aerobic program followed by home intervention consisting of functional exercise training and enhanced physical activity with nurse telephonic behavioral support
Study NCT01308008 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: flex and toning health education program
Description: Initial flex and toning program continued on follow-up along with health education
Study NCT00535561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate tablets 325 mg, po, TID
Study NCT00535561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate plus levothyroxine
Description: Combination of ferrous sulfate tablet 325mg plus levothyroxine tablet 25 micrograms, po, TID
Study NCT00784420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UK-453,061
Description: UK-453,061 1000 mg once daily for 10 days
Study NCT00784420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UK-453,061
Description: UK-453,061 1000 mg once daily for 10 days
Study NCT00784420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: Raltegravir 400 mg twice daily for 10 days
Study NCT00784420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir 400 mg twice daily for 10 days
Study NCT03992508 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent pneumatic compression
Study NCT03992508 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: complex decongestive therapy
Study NCT03992508 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: complex decongestive therapy
Study NCT02892474 — intervention group
Intervention type: PROCEDURE
Intervention: Hybrid Coronary Revascularization (HCR)
Description: Hybrid coronary revascularization (HCR) is a combination of surgery and catheter procedures to open up clogged heart arteries. HCR is the intentional combination of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI). The HCR strategy combines grafting of the left anterior descending artery (LAD) coronary artery using the left internal mammary artery (LIMA) with PCI of non-LAD coronary stenoses. Drug-eluting stents are substituted for saphenous vein grafts (SVG) for non-LAD coronary targets, and the surgical LIMA to LAD bypass is performed, ideally through a minimally invasive, limited access, sternal-sparing approach.
Study NCT02892474 — intervention group
Intervention type: PROCEDURE
Intervention: Coronary Artery Bypass Grafting (CABG)
Description: Coronary artery bypass grafting (CABG) is a surgery to create a new path for blood flow to the heart. A healthy section of vein or artery from elsewhere in the patient's body will be attached to the coronary artery just above and below the area of concern, to create a way for blood to bypass the blocked part of the coronary artery.
Study NCT02011321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clevidipine
Description: clevidipine infusion x4 hours
Study NCT02655432 — intervention group
Intervention type: DEVICE
Intervention: Spot photoscreener
Description: Screening of vision problem through an automated device
Study NCT02655432 — intervention group
Intervention type: PROCEDURE
Intervention: Ophthalmologic evaluation
Description: Screening of vision problem through an ophthalmologic evaluation
Study NCT02655432 — intervention group
Intervention type: PROCEDURE
Intervention: Cyclopleged refraction
Description: Screening of refractive problems through a cyclopleged optometric refraction
Study NCT01735487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Own Brand cigarette
Description: Smoke, 15 puff of, Own Brand cigarettes;
Study NCT01735487 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Own Brand cigarette
Description: Smoke, 15 puff of, Own Brand cigarettes;
Study NCT01735487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: one high 2,4% nicotine
Description: Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine
Study NCT01735487 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: one high 2,4% nicotine
Description: Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine
Study NCT01735487 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: one high 2,4% nicotine
Description: Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine
Study NCT01735487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: original 7,4 mg nicotine
Description: Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
Study NCT01735487 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: original 7,4 mg nicotine
Description: Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
Study NCT01735487 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: original 7,4 mg nicotine
Description: Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
Study NCT01735487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nicotine free
Description: smoke, 15 puff, of electronic cigarette nicotine free
Study NCT01735487 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nicotine free
Description: smoke, 15 puff, of electronic cigarette nicotine free
Study NCT01735487 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ego 9mg
Description: smoke, 15 puff, of electronic cigarette Ego 9 mg
Study NCT01735487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ego 9mg
Description: smoke, 15 puff, of electronic cigarette Ego 9 mg
Study NCT01735487 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ego 9mg
Description: smoke, 15 puff, of electronic cigarette Ego 9 mg
Study NCT00198380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib 250 mg/day, until progression or severe toxicity
Study NCT01033734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oseltamivir [Tamiflu]
Description: 5-day course (10 doses), intravenous administration, may be switched to oral administration at the discretion of the investigator; up to 5 additional days of treatment possible.
Study NCT03428893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Application
Description: Participants will receive usual care physical therapy guided by Clinical Practice Guidelines and based on individual symptoms and need over 7 in-person visits. Measures will be collected by the physical therapist related to leg strength, balance, fitness, and mobility as part of the usual care physical therapy evaluation and follow-up. The treating physical therapist will negotiate the physical therapy intervention based on patient preferences and goals and assessment findings. Using clinical practice guidelines, the intervention for the research participants is expected to address deficits in strength, mobility, balance, and cardiovascular endurance. Exercise prescription will be provided using the Wellpepper physical therapy exercise prescription mobile app.
Study NCT00639483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg oral capsules twice daily as add-on therapy to risperidone twice daily (range 2-8 mg/day) for 11 weeks
Study NCT00639483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched oral placebo as add-on to risperidone twice daily (range 2-8 mg/day) for 11 weeks
Study NCT02388438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bongener
Study NCT04176263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBT
Description: The SBT group will receive a 4-week split-belt treadmill training, 3 times a week using a standardized progression protocol. The sessions, including breaks, will approximately take 1 hour each. The training will be given by a trainer experienced with PD.
Study NCT04176263 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TBT
Description: The TBT group will receive a 4-week tied-belt treadmill training, 3 times a week. To make sure exposure of the two interventions is similar the sessions of the TBT group will be of similar length and progression level (approximately 1 hour each). The training will be given by a trainer experienced with PD.
Study NCT03080298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP101
Study NCT03080298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03095742 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Low MAP
Description: Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein
Study NCT03095742 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: High MAP
Description: Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein
Study NCT04640272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBM-007
Description: Intravitreal injection
Study NCT03487575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Open trial
Description: Integrated electronic support and care support manager contact
Study NCT02409589 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG
Description: The ECG-guided PICC tip detection method will be used to identify catheter tip location during the procedural placement of the catheter. This method involves an ECG monitor which will be connected to the guidewire used for catheter placement. The changes in the ECG p-wave will guide correct PICC placement. An X-ray radiograph will be conducted to confirm the tip location after PICC placement.
Study NCT02409589 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surface prediction length method
Description: The method will estimate the length of the catheter from puncture site to the junction of superior vena cava / right atrium (SVC-RA) . Tip location is placed according to the estimated length but later on will be determinated by chest X-ray performed after the placement procedure. If the tip location is not at an ideal place, additional procedures and X-ray radiograph would be required in order to ensure proper tip location.
Study NCT02538874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986171
Study NCT02538874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02831413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RS+
Description: The curriculum's 12 sessions will be delivered over a period of about 12 weeks during the winter quarter, with an average of one session taught per week. The lessons cover topics such as personal values, the principals of smart relationships, communication and conflict management, and sexual decision making.
Study NCT02831413 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Codeacademy
Description: a computer programming curriculum, Codeacademy, that teaches students how to use HTML.
Study NCT04548726 — intervention group
Intervention type: DEVICE
Intervention: Sapien 3 Transcather Aortic Valve Implant
Description: Implant of a Ballon Expandable Aortic Valve Sapien 3 (Edwards Lifesciences, Irvine, CA, USA) prosthesis via a transcatheter procedure.
Study NCT04548726 — intervention group
Intervention type: DEVICE
Intervention: Myval Transcather Aortic Valve Implant
Description: Implant of a Ballon Expandable Aortic Valve Myval (Meril Life Sciences Pvt. Ltd., India) prosthesis via a transcatheter procedure.
Study NCT02070029 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture Therapy - Initial Evaluation History including: chief complaint, diet, level of diaphoresis, water intake, digestive function, menstrual cycling, sleep habits, overall mood.~Physical Exam: inspection of tongue and palpation of central and peripheral pulses.~Chinese Diagnoses for Female Sexual Dysfunction: Kidney Yang Deficiency; Liver Qi Stagnation; Generalized Blood Deficiency; Spleen Yang Deficiency; Heart Fire~- Subsequent Sessions 25 minute sessions, twice weekly, for 5 weeks = total 10 sessions Needle usage = 8-20, average 14 per session Typically placed on the scalp, lower abdomen, elbows and knees